Toronto Dominion Bank Boosts Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Toronto Dominion Bank raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 17,298.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,704 shares of the company’s stock after buying an additional 20,585 shares during the period. Toronto Dominion Bank’s holdings in Teva Pharmaceutical Industries were worth $336,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. New Covenant Trust Company N.A. purchased a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter worth $28,000. EntryPoint Capital LLC purchased a new stake in Teva Pharmaceutical Industries in the first quarter worth about $30,000. Beach Investment Counsel Inc. PA bought a new position in shares of Teva Pharmaceutical Industries in the second quarter worth about $48,000. Byrne Asset Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $52,000. Finally, Industrial Alliance Investment Management Inc. bought a new stake in Teva Pharmaceutical Industries during the 1st quarter worth approximately $54,000. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $18.02 on Tuesday. The stock has a market cap of $20.42 billion, a price-to-earnings ratio of -43.95, a PEG ratio of 1.21 and a beta of 0.88. Teva Pharmaceutical Industries Limited has a 12 month low of $8.06 and a 12 month high of $19.08. The company has a 50 day simple moving average of $17.76 and a two-hundred day simple moving average of $16.25. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The business had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on TEVA shares. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Wednesday, July 10th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Monday, September 23rd. Jefferies Financial Group raised their price objective on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Barclays boosted their target price on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average target price of $18.89.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the transaction, the insider now directly owns 45,060 shares of the company’s stock, valued at approximately $777,285. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.